Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 4
2021 2
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.
Leest PV, Janning M, Rifaela N, Azpurua MLA, Kropidlowski J, Loges S, Lozano N, Sartori A, Irwin D, Lamy PJ, Hiltermann TJN, Groen HJM, Pantel K, Kempen LCV, Wikman H, Schuuring E. Leest PV, et al. Int J Mol Sci. 2023 Aug 29;24(17):13390. doi: 10.3390/ijms241713390. Int J Mol Sci. 2023. PMID: 37686200 Free PMC article.
Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.
Nitschke C, Markmann B, Walter P, Badbaran A, Tölle M, Kropidlowski J, Belloum Y, Goetz MR, Bardenhagen J, Stern L, Tintelnot J, Schönlein M, Sinn M, van der Leest P, Simon R, Heumann A, Izbicki JR, Pantel K, Wikman H, Uzunoglu FG. Nitschke C, et al. Among authors: van der leest p. Clin Chem. 2023 Mar 1;69(3):295-307. doi: 10.1093/clinchem/hvac214. Clin Chem. 2023. PMID: 36644936
A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice.
Kramer A, Schuuring E, Vessies DCL, van der Leest P, Geerlings MJ, Rozendal P, Lanfermeijer M, Linders TC, van Kempen LC, Fijneman RJA, Ligtenberg MJL, Meijer GA, van den Broek D, Retèl VP, Coup VMH; COIN Consortium. Kramer A, et al. Among authors: van der leest p. J Mol Diagn. 2023 Jan;25(1):36-45. doi: 10.1016/j.jmoldx.2022.10.004. Epub 2022 Nov 17. J Mol Diagn. 2023. PMID: 36402278 Free article.
Dutch National Round Robin Trial on Plasma-Derived Circulating Cell-Free DNA Extraction Methods Routinely Used in Clinical Pathology for Molecular Tumor Profiling.
van der Leest P, Ketelaar EM, van Noesel CJM, van den Broek D, van Boerdonk RAA, Deiman B, Rifaela N, van der Geize R, Huijsmans CJJ, Speel EJM, Geerlings MJ, van Schaik RHN, Jansen MPHM, Dane-Vogelaar R, Driehuis E, Leers MPG, Sidorenkov G, Tamminga M, van Kempen LC, Schuuring E. van der Leest P, et al. Clin Chem. 2022 Jul 3;68(7):963-972. doi: 10.1093/clinchem/hvac069. Clin Chem. 2022. PMID: 35616097 Clinical Trial.
Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling.
Weber S, Spiegl B, Perakis SO, Ulz CM, Abuja PM, Kashofer K, Leest PV, Azpurua MA, Tamminga M, Brudzewsky D, Rothwell DG, Mohan S, Sartori A, Lampignano R, Konigshofer Y, Sprenger-Haussels M, Wikman H, Bergheim IR, Kloten V, Schuuring E, Speicher MR, Heitzer E. Weber S, et al. Among authors: leest pv. Cancers (Basel). 2020 Jun 16;12(6):1588. doi: 10.3390/cancers12061588. Cancers (Basel). 2020. PMID: 32560092 Free PMC article.
Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Weber S, van der Leest P, Donker HC, Schlange T, Timens W, Tamminga M, Hasenleithner SO, Graf R, Moser T, Spiegl B, Yaspo ML, Terstappen LWMM, Sidorenkov G, Hiltermann TJN, Speicher MR, Schuuring E, Heitzer E, Groen HJM. Weber S, et al. Among authors: van der leest p. JCO Precis Oncol. 2021 Nov;5:1540-1553. doi: 10.1200/PO.21.00182. JCO Precis Oncol. 2021. PMID: 34994642
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
van der Leest P, Hiddinga B, Miedema A, Aguirre Azpurua ML, Rifaela N, Ter Elst A, Timens W, Groen HJM, van Kempen LC, Hiltermann TJN, Schuuring E. van der Leest P, et al. Mol Oncol. 2021 Nov;15(11):2910-2922. doi: 10.1002/1878-0261.13090. Epub 2021 Sep 25. Mol Oncol. 2021. PMID: 34449963 Free PMC article.
12 results